Drugs / GSK3923868
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06597500 | Sep → Dec 2024 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT06577597 | Sep → Nov 2024 | respiratory tract infectious disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT05677347 | Jan → Jul 2023 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT05398198 | Jun 2022 → Apr 2024 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT04585009 | Oct 2020 → Jun 2022 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3923868 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05398198 ↗ |
| Route | Inhaled | “GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.” NCT04585009 ↗ |